Saeed A. Chowdhry, MD
With the advancements in traumatic wound care, the question is no longer whether we can close the wound — it’s how well we can restore what was lost.
Key Takeaways:
Wound closure has long been the default measure of success in acute wound care; however, for patients, it is rarely the milestone that matters.Regenerative technologies, including autologous cell systems and dermal scaffolds, now enable higher-quality, more functional outcomes.Published evidence links these approaches to shorter hospital stays and meaningful per-patient cost reductionsHealth systems that follow the patient beyond discharge are uncovering substantial human and financial value that episode-based metrics miss.
Closure is a milestone, not an outcome.
There is a moment when treating a traumatic wound where surgeons feel their objective is complete: the wound is closed, the graft is intact, and the dressing is clean. For decades, closure has been considered the primary measure of success, shaping how we train surgeons, design care pathways, evaluate technologies, and report results. Nearly all of the metrics we track, the benchmarks we set, and the reimbursement structures we’ve built are anchored to this point.
Meanwhile, patients go home with grafted skin that pulls tight across their shoulder when they reach for a shelf. They avoid sleeveless shorts. They decline handshakes. They leave jobs that require physical labor. They carry the wound long after the chart says it’s closed.
We can, and should, do better for our patients, and technology is available now to demand more.
Skin Does More Than Blanket the Body
Skin is not decorative. It regulates body temperature, guards against infection, enables sensation, and provides the pliable architecture that enables movement. When trauma or burns occur, replacing the injured skin should be considered the bare minimum — not the goal.
Split-thickness skin grafting, the dominant technique for decades, is good at coverage but less effective for restoration. Grafts frequently differ in color and texture from native skin. They can stiffen and contract, especially over joints, creating a permanent mechanical disadvantage in the very body part the patient needs most. The donor harvest site opens a second wound that can be extremely painful, cause secondary infection, and scar visibly.
We have accepted these trade-offs because, for a long time, coverage was enough. It no longer is. It should now be the bare minimum.
Aligning Measurement with Technological Advances
Regenerative medicine has quietly transformed what is possible in reconstructive surgery. Point-of-care autologous cell systems can now take a skin sample the size of a postage stamp, process the patient’s own cells, and deliver them directly to a wound, supporting tissue regeneration that more closely mirrors native skin in pigmentation, pliability, and quality. It’s been found that in patients with deep partial-thickness burns, treatment with spray-on skin cell technology alone significantly reduced donor skin requirements by 97.5% compared to 2:1 meshed autografting. Smaller donor sites mean less pain and faster recovery. Better tissue quality means less contracture and better long-term mobility. Faster closure means less risk of infection. Combined, the patient leaves the hospital sooner to recover at home.
Dermal scaffold technologies are rebuilding the foundation beneath grafts, accelerating vascularization, and creating the biological conditions for durable, resilient tissue. These are not experimental curiosities but available tools that surgeons are already putting to use.
However, adoption remains uneven, largely because incentive structures don’t reward the outcomes these technologies improve. If a health system’s wound care program is evaluated on closure rates and length of stay, there is no data signal for “patient returned to full shoulder mobility” or “no revision surgery required at 18 months.” The benefit is real. It just isn’t measured.
The Cost Argument Is Stronger Than You Think
Advanced therapies do cost more upfront. Unfortunately, this is also where the analysis often stops, and where it shouldn’t.
A patient who avoids scar contracture does not require revision surgery. A patient with better donor-site healing is discharged sooner and requires less pain management. A trauma survivor who regains full function returns to work instead of entering a disability pathway. Studies have found that spray-on skin technology can reduce hospital length of stay by an average of 3.3 days, resulting in cost savings of nearly $37,000 per patient with burns of up to 50% TBSA. Economic modeling suggests hospital length of stay alone accounts for up to 70% of those cost reductions. When you follow the downstream economics rather than stopping at the initial procedure cost, the math adds up.
Health systems that have built the data infrastructure to track functional outcomes, readmissions, and long-term resource utilization are beginning to see this. Those still measuring wound care success at the point of closure are measuring the episode, not the recovery. The difference, in both human and financial terms, is significant.
What We Owe Patients and Ourselves
For a trauma survivor, feeling comfortable in their skin is not a luxury outcome. It is the point. The ability to move without restriction, to feel comfortable in their appearance, to return to work and relationships, and just plain old ordinary life is what recovery actually means to the person living it.
Healthcare leaders have both the opportunity and the obligation to build systems that pursue that standard. That means updating outcome frameworks to capture function, aesthetics, and quality of life. It means evaluating wound care technologies against the full arc of patient recovery, not just the acute episode. And it means being willing to challenge the comfortable assumption that closure is enough.
The tools to do better exist, and the evidence is there. The only thing still lagging is the willingness to redefine what success looks like and to hold our systems accountable for achieving it.
Closing a wound is where surgery ends. Restoring a life is where care begins.
About Saeed A. Chowdhry, MD
Saeed A. Chowdhry, MD, has a busy clinical practice in the Chicago area and also serves as Associate Professor of Plastic Surgery at the Rosalind Franklin University of Medicine and Science, also known as The Chicago Medical School. Dr. Chowdhry is the Chairman and Chief of Plastic Surgery at Christ Hospital in the Chicago area. With close to 800 beds, it is one of the busiest Level I trauma centers and tertiary care referral centers in the Midwest.
He was educated at Rush University College of Medicine and subsequently completed his General Surgery training at the University of Illinois at Mt. Sinai and Plastic Surgery fellowship training at the University of Louisville. While in training and in practice, he has won several research and teaching awards. He has authored peer-reviewed journal articles and book chapters that have been reviewed and cited over a thousand times in the surgical literature. Dr. Chowdhry has also served as a reviewer for several journals as well as the Cochrane Review and has been recognized for his expertise in reconstructive and cosmetic surgery.
